roy

Which statement made by the PMHNP correctly describes the relationship between NE neurons and pharmaceutical treatment?

1. Which statement made by the PMHNP correctly describes the relationship between NE neurons and pharmaceutical treatment? A. “Drugs inhibit the release of NE.” B. “Drugs can mimic the natural functioning of the NE neuron.” C. “Drugs are unable to simulate the effects of NE neurons.” D. “Drugs prevent the natural functioning of the NE […]

Which statement made by the PMHNP correctly describes the relationship between NE neurons and pharmaceutical treatment? Read More »

The PMHNP understands that which action of norepinephrine will affect Ms. Boeckhs serotonin levels?

1. Ms. Boeckh is a 42-year-old patient with major depression. The PMHNP understands that which action of norepinephrine will affect Ms. Boeckh’s serotonin levels? A. Norepinephrine potentiates 5HT release through a2 postsynaptic receptors. B. Norepinephrine inhibits 5HT release through a2 receptors. C. Norepinephrine inhibits α2 receptors on axon terminals. D. Norepinephrine potentiates 5HT release through

The PMHNP understands that which action of norepinephrine will affect Ms. Boeckhs serotonin levels? Read More »

What does the PMHNP understand regarding this patient’s response to selective serotonin reuptake inhibitor (SSRI)/SNRI treatment?

1. The PMHNP is caring for a patient with the s genotype of SERT. What does the PMHNP understand regarding this patient’s response to selective serotonin reuptake inhibitor (SSRI)/SNRI treatment? A. The patient has a higher chance of tolerating SSRI/SNRI treatment. B. The patient will have a positive response to SSRI/SNRI treatment. C. The patient

What does the PMHNP understand regarding this patient’s response to selective serotonin reuptake inhibitor (SSRI)/SNRI treatment? Read More »

Why does the PMHNP avoid treating a patient with cyclothymia, and has major depressive episodes, with antidepressant monotherapy?

1. Why does the PMHNP avoid treating a patient with cyclothymia, and has major depressive episodes, with antidepressant monotherapy? A. The patient may experience paranoid avoidant behavior. B. The patient may experience severe depression. C. The patient may experience auditory hallucinations. D. The patient may experience increased mood cycling. Place Your Order Here!

Why does the PMHNP avoid treating a patient with cyclothymia, and has major depressive episodes, with antidepressant monotherapy? Read More »

The PMHNP recognizes that which patient would be contraindicated for antidepressant monotherapy?

1. The PMHNP recognizes that which patient would be contraindicated for antidepressant monotherapy? A. Patient with a bipolar I designation B. Patient with a bipolar II designation C. Patient with a bipolar III designation D. None of the above Place Your Order Here!

The PMHNP recognizes that which patient would be contraindicated for antidepressant monotherapy? Read More »

What does the PMHNP infer about the patients prescription based on this documentation?

1. Ms. Ryerson is a 28-year-old patient with a mood disorder. She recently requested to transfer to a new PMHNP, after not getting along well with her previous provider. The new PHMNP is reviewing Ms. Ryerson’s medical chart prior to their first appointment. Upon review, the PMHNP sees that the former provider last documented “patient

What does the PMHNP infer about the patients prescription based on this documentation? Read More »

Which receptor action in antipsychotic medications is believed to be the most beneficial in producing the effects described by Mr. Gordon?

1. Mr. Gordon is a middle-aged patient who is taking antipsychotics. When meeting with the PMHNP, he reports positive responses to the medication, stating, “I really feel as though the effects of my depression are going away.” Which receptor action in antipsychotic medications is believed to be the most beneficial in producing the effects described

Which receptor action in antipsychotic medications is believed to be the most beneficial in producing the effects described by Mr. Gordon? Read More »

Which response by the PMHNP describes nthe factors that contribute to reduced risk of extrapyramidal symptoms (EPS) for patients who take antipsychotics?

1. The student inquires about antipsychotic medications. Which response by the PMHNP describes nthe factors that contribute to reduced risk of extrapyramidal symptoms (EPS) for patients who take antipsychotics? A. Those that are potent D2 antagonists B. Those that are potent D2 antagonists with 5HT2A antagonism properties C. D2 receptors that are blocked in the

Which response by the PMHNP describes nthe factors that contribute to reduced risk of extrapyramidal symptoms (EPS) for patients who take antipsychotics? Read More »

Which risk factors are most likely to contribute to a person developing tardive dyskinesia (TD)?

1. The PMHNP is taking a history on a patient who has been on antipsychotics for many years. Which risk factors are most likely to contribute to a person developing tardive dyskinesia (TD)? A. Long-term use of antipsychotics B. Genetic disposition C. Age D. A and C E. All of the above Place Your Order

Which risk factors are most likely to contribute to a person developing tardive dyskinesia (TD)? Read More »